

Executive Summary

“This cancer treatment platform, based on 30 years in the pharmaceutical industry where my primary focus was on development of cancer treatments, has the highest potential in my view to change the paradigm of treatment of patients with many types of solid and hematological cancers, resulting in long term survival.

Given the extensive global patent protection through 2040, the commercial value of this platform is high, both as monotherapy and in combination.”

Dr. Robert Ryan, CEO

Summary

Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate with patient outcome. The lead humanized mAb has been selected and is designated as IVT-8086. Innova’s platform technology is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer, multiple myeloma and pancreatic cancer. The opportunity for this anticancer therapy as a monotherapy and in combination with other chemotherapy agents will expand across other solid tumors. The focus on pediatric osteosarcoma as one of the initial targets will allow a fast-regulatory approval.

Osteosarcoma is a rare disease which was granted both orphan designation and rare pediatric disease designation from the FDA, which will expedite the regulatory approval timeline including the opportunity to obtain a Rare Pediatric Disease priority review voucher. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, with revenue ranging between \$80M and \$350M (most recent voucher sales in \$100-120M range). SFRP2 has been further validated as an important molecular target across human cancers, where expression levels have been shown to correlate with patient outcome. A diagnostic is also in development which will be assessed as a potential marker for early cancer detection, as well as a prognostic marker for assessing therapeutic benefit of treatments and assessment of potential reoccurrence of cancer. **The program patent portfolio consists of 35+ patents ensuring global protection through 2042 and beyond.**

Company Description and Experienced Management Team

Innova Therapeutics was founded on the research conducted by Co-founders Nancy Klauber-DeMore, MD, FACS, Professor of Surgery and BMW Endowed Chair Cancer Research, Medical University of South Carolina (MUSC) and Cam Patterson, MD, MBA who is currently the Chancellor, University of Arkansas for Medical Sciences.

Innova is comprised of a highly experienced management/development team with a successful track record of building new companies, developing effective therapeutics and successful partnering/exits. All members have more than 20 years of global drug development experience covering all functional areas, including extensive cancer therapy development. The team is led by one of the co-founders and CEO, Robert Ryan, Ph.D., who is a successful serial biotech entrepreneur. Key functional expertise including clinical, regulatory, preclinical, and manufacturing, and business development are provided by the team within Innova Therapeutics.

Innova has Developed a Novel Anti-Cancer Platform and Diagnostic

Secreted frizzled-related protein-2 (SFRP2) is a novel anticancer therapeutic target that is highly expressed across most solid cancers (including primary and metastatic disease). SFRP2 is secreted by tumor cells, endothelial cells, and activated T-cells. SFRP2 selectively modulates the non-canonical Wnt/Calcium (Ca²⁺)-signaling cascade in different cancers, which plays a role in a series of cellular processes including

Executive Summary


angiogenesis, cell survival, cell migration and metastasis, and production of T-cell exhaustion SFRP2 binds to the frizzled 5 precursor (FZD5) receptor and activates the calcineurin/nuclear factor (NFATc3) pathway.

IVT-8086 inhibits SFRP2 in cancer and has multi-faceted activities in multiple cell types associated with cancer as shown in Figure 1, including:

- **Tumor cells** - reduced tumor growth (primary and metastatic disease), including increased apoptosis.
- **Tumor endothelial cells** - reduced angiogenesis resulting in reduced migration and metastasis.
- **Activated T-Cells** - rescues T Cell that become dysfunctional including T Cell exhaustion, impacting expression of PD-1 and CD38.


Figure 1: Schematic of Impact of SFRP2 on Common Pathway Across 3 Key Tumor Microenvironment Cell Types

There is no therapeutic that impacts these 3 cell types simultaneously across both solid and hematological malignancies.



The Cancer Genome Atlas (TCGA) SFRP2 expression in Human Tumors

SFRP2 is Overexpressed Across Many Tumor Types



Executive Summary

The competitive advantage of IVT-8086 is that it simultaneously targets both the tumor and the tumor microenvironment, without targeting normal cells, exploiting a common pathway across most cancers. The lead humanized SFRP2 mAb has been selected, IVT-8086, and has been shown to antagonize SFRP2 by selectively blocking the non-canonical Wnt/Ca²⁺ pathway in tumor cells, activated T-cells, and tumor endothelial cells. IVT-8086 monotherapy treatment has demonstrated efficacy (**with no adverse safety effects**) in multiple animal models implanted with either human xenografts or genetically engineered mouse model (GEMM) cell lines. In addition, combination therapy with IVT-8086 and PD-1 mAb has demonstrated synergistic efficacy with no noted safety concerns.

Recent data which has been published has demonstrated that in pancreatic ductal adenocarcinoma (PDAC) SFRP2 is regulated by KRAS, which is the most lethal mutation seen in pancreatic cancer....blockage of this pathway should have beneficial outcomes to patients with this cancer. In patients with PDAC, SFRP2 is prognostic for survival.

SFRP2 has been further validated as an important molecular target across human cancers, where expression levels have been shown to correlate with patient outcome. A diagnostic is in development which will be assessed as a potential diagnostic for early cancer detection, as well as a prognostic marker for assessing therapeutic benefit of treatments and assessment of potential reoccurrence of cancer.

Competitive Landscape

Treatment options for many cancers are limited due to inadequate efficacy and/or significant toxicity. In particular, metastatic osteosarcoma (OS) is a deadly disease in which patients often have treatment-resistant disease, resulting in survival rates of only 15 to 30%. In the last 20 years, OS patients have not seen improvement in prognosis with available treatments. Consequently, new therapies are needed. Similar limited treatment options currently are also present in patients with sarcoma, multiple myeloma, pancreatic cancer, and triple negative breast (TNB) cancer, which are the cancers of initial focus for Innova. We have demonstrated compelling efficacy with no adverse effects with our therapy in these indications both as monotherapy and in combination in animal *in vitro* and *in vivo* models.

Recent Research and Market Reports have indicated that the opportunity for more effective and safe therapies in the treatment of cancer with monoclonal antibodies are needed both as monotherapy and in combination with Checkpoint inhibitors: **The global monoclonal antibodies market currently valued at \$180.5 billion, with by 2030, this market is estimated to reach >\$520 billion; and Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) is currently in excess of US\$ 100 Billion.**

There are currently no diagnostics that have broad implications for assessing early-stage cancer across various solid and hematological malignancies. Measurement of SFRP2 in blood has the potential to be the first diagnostic for early detection across multiple cancers, along with use as a monitoring test for confirming remission and possible reoccurrence of cancer in patients.

Financing and Exit Strategy

A total of approximately \$11M in non-dilutive funds has been obtained to date to fund the development of the humanized monoclonal antibody (IVT-8086), including key activities such as preclinical mechanistic studies, animal tumor model studies assessing efficacy and safety across several solid tumors, clinical validation studies, and expanding IP.

Executive Summary

We are currently raising an initial financing of US\$15M to support activation of the IND and initiation of Phase 1, with a second financing anticipated within a year of \$25M to support the proposed clinical development program with our lead candidate, IVT-8086, in multiple cancers both as monotherapy and in combination. The financing will also be used to develop our diagnostic which will be used in the clinical program.

The options for substantial exits for the cancer therapy and diagnostic are broad, including partnering/collaboration once clinical data is obtained, partnering in specific territories, or continued expansion of cancer indications to increase value of the program. Regardless of the pathway, the market value for a broad effective therapy of this type would be in excess of \$5B, with the value of an effective early cancer diagnostic test in excess of \$1B.